Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalSTU:IC7 80 OCF Yield % is 5.17 as of Aug. 17, 2026, which is 35% above its 10-year median of 3.84. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 850 Medical Devices & Instruments companies, ICU Medical ranks better than 68% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
ICU Medical OCF Yield % Related Terms
ICU Medical OCF Yield % Historical Data
* Premium members only.
The historical data trend for ICU Medical's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IC7 vs NVST, MMSI, MMED: OCF Yield % Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's OCF Yield % distribution charts can be found below:
* The bar in red indicates where ICU Medical's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (STU:IC7) has a OCF Yield % of 5.17 as of Aug. 17, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on ICU Medical and its competitors. This is 35% above median its historical median of 3.84. According to the industry distribution chart, ICU Medical ranks #272 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 32%.
Is ICU Medical's OCF Yield % too high?
ICU Medical's current OCF Yield % of 5.17 is 35% above median its 10-year median of 3.84. The Medical Devices & Instruments industry median OCF Yield % is 1.53. ICU Medical's value of 5.17 is 239% above this industry median. Based on the distribution chart, ICU Medical ranks #272 out of 850 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's OCF Yield % compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #272 out of 850 companies for OCF Yield %. This puts ICU Medical in the upper half of its industry. The industry median OCF Yield % is 1.53. ICU Medical's value of 5.17 is 239% above this benchmark. While the company's 10-year median is 3.84 vs. the industry median of 1.53, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.53, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current OCF Yield % of 5.17 is 239% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on ICU Medical and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current OCF Yield % is 5.17, which is 35% above median its own 10-year median of 3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current OCF Yield % is 5.17, which is 35% above median its 10-year median of 3.84 and 239% above the Medical Devices & Instruments industry median of 1.53. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current OCF Yield % is 5.17 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (STU:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for STU:IC7:
OCF Yield %: 5.17 (35% above median its 10-year median of 3.84)
GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
Industry Position: 239% above the Medical Devices & Instruments median (#272 of 850)
No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score
Get the complete analysis for STU:IC7
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IC7 has been successfully added to your 
